Risk Alleles of USF1 Gene Predict Cardiovascular Disease of Women in Two Prospective Studies

Upstream transcription factor 1 (USF1) is a ubiquitously expressed transcription factor controlling several critical genes in lipid and glucose metabolism. Of some 40 genes regulated by USF1, several are involved in the molecular pathogenesis of cardiovascular disease (CVD). Although the USF1 gene has been shown to have a critical role in the etiology of familial combined hyperlipidemia, which predisposes to early CVD, the gene's potential role as a risk factor for CVD events at the population level has not been established. Here we report the results from a prospective genetic–epidemiological study of the association between the USF1 variants, CVD, and mortality in two large Finnish cohorts. Haplotype-tagging single nucleotide polymorphisms exposing all common allelic variants of USF1 were genotyped in a prospective case-cohort design with two distinct cohorts followed up during 1992–2001 and 1997–2003. The total number of follow-up years was 112,435 in 14,140 individuals, of which 2,225 were selected for genotyping based on the case-cohort study strategy. After adjustment for conventional risk factors, we observed an association of USF1 with CVD and mortality among females. In combined analysis of the two cohorts, female carriers of a USF1 risk haplotype had a 2-fold risk of a CVD event (hazard ratio [HR] 2.02; 95% confidence interval [CI] 1.16–3.53; p = 0.01) and an increased risk of all-cause mortality (HR 2.52; 95% CI 1.46–4.35; p = 0.0009). A putative protective haplotype of USF1 was also identified. Our study shows how a gene identified in exceptional families proves to be important also at the population level, implying that allelic variants of USF1 significantly influence the prospective risk of CVD and even all-cause mortality in females.

[1]  P. Arner,et al.  Upstream transcription factor-1 gene polymorphism is associated with increased adipocyte lipolysis. , 2005, The Journal of clinical endocrinology and metabolism.

[2]  L. Peltonen,et al.  USF1 and dyslipidemias: converging evidence for a functional intronic variant. , 2005, Human molecular genetics.

[3]  Päivi Pajukanta,et al.  Familial Combined Hyperlipidemia in Mexicans: Association With Upstream Transcription Factor 1 and Linkage on Chromosome 16q24.1 , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Ng,et al.  The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population , 2005, Diabetologia.

[5]  L. Peltonen,et al.  Evaluating whole genome amplification via multiply-primed rolling circle amplification for SNP genotyping of samples with low DNA yield. , 2005, Twin research and human genetics : the official journal of the International Society for Twin Studies.

[6]  H. Coon,et al.  Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides , 2005, Human Genetics.

[7]  V. Salomaa,et al.  The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[8]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[9]  Sangita Kulathinal,et al.  MORGAM (an international pooling of cardiovascular cohorts). , 2004, International journal of epidemiology.

[10]  D. Tregouet,et al.  Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. , 2004, Human molecular genetics.

[11]  L. Peltonen,et al.  Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1) , 2004, Nature Genetics.

[12]  V. Salomaa,et al.  Continuous 15-Year Decrease in Incidence and Mortality of Stroke in Finland: The FINSTROKE Study , 2004, Stroke.

[13]  H. Tunstall-Pedoe,et al.  MONICA Monograph and Multimedia Sourcebook , 2003 .

[14]  V. Salomaa,et al.  Trends in coronary events in Finland during 1983-1997. The FINAMI study. , 2003, European heart journal.

[15]  L. Peltonen,et al.  A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. , 2000, Genome research.

[16]  E. Vartiainen,et al.  Cardiovascular risk factor changes in Finland, 1972-1997. , 2000, International journal of epidemiology.

[17]  J. Virtamo,et al.  Validation of stroke diagnosis in the National Hospital Discharge Register and the Register of Causes of Death in Finland , 1999, European Journal of Epidemiology.

[18]  J. Virtamo,et al.  Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland , 1997, European Journal of Epidemiology.

[19]  W. Barlow,et al.  Robust variance estimation for the case-cohort design. , 1994, Biometrics.

[20]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[21]  C. Mathew,et al.  Blot hybridisation analysis of genomic DNA. , 1984, Journal of medical genetics.

[22]  L. J. Wei,et al.  The Robust Inference for the Cox Proportional Hazards Model , 1989 .